A pivotal FDA meeting on Biogen’s Alzheimer’s treatment is near. Here’s what you need to know
Here’s what you need to know about aducanumab, the controversy around it, and the issues that will take center stage at the FDA meeting.
Read The StoryBiotech
Inside the discoveries, personalities, and deals driving drug development. Sign up for The Readout newsletter to get the latest on biotech delivered to your inbox. And subscribe to STAT Plus to access daily, market-moving coverage of the biotech sector — from startup funding to clinical trial readouts
New rare disease gene therapy startup recruits former Sarepta executive as CEO
Gilead announces long-awaited price for Covid-19 drug remdesivir
Selling stock like clockwork, Moderna’s top doctor gets $1 million richer every week
New data on Gilead’s remdesivir, released by accident, show no benefit for coronavirus patients. Company still sees reason for hope
All Coverage
advertisement
